Background & Aims: Response-guided therapy has been confirmed to be an effective strategy for the treatment of chronic hepatitis C in the pegylated interferon (PegIFN) era, but no randomized trial utilizing this strategy has been conducted in chronic hepatitis B.
Methods:
In this open-label, multicenter, randomized trial, HBeAg positive patients were treated with PegIFN (180 lg/week) for 24 weeks. Early responders (HBsAg <1500 IU/ml and HBV DNA <10 5 copies/ml at week 24) received PegIFN for a further 24 weeks (arm A), while non-early responders were randomized to PegIFN for another 24 weeks (arm B), another 72 weeks (arm C) or PegIFN for another 72 weeks plus adefovir for 36 weeks (arm D). The primary endpoint was the change of quantitative HBsAg from baseline to the end of follow-up (EOF).
Results: For non-early responders, 96-week PegIFN monotherapy did not lead to a greater reduction of HBsAg from baseline to EOF, compared with 48-week PegIFN (À0.71 vs. À0.67 log 10 IU/ml, P = 0.407). The rate of HBeAg seroconversion with HBV DNA <2000 IU/ml at EOF were similar for arms B, C and D (17.9%, 23.9% and 25.0% respectively). For patients with HBsAg <1500 IU/ml or HBV DNA <10 5 copies/ml at week 24, 38.4% and 37.0% achieved HBeAg seroconversion with HBV DNA <2000 IU/ ml at EOF respectively. Conclusions: Patients with HBsAg <1500 IU/ml or HBV DNA <10 5 copies/ml at week 24 would benefit from continued PegIFN treatment. Extending the duration of PegIFN with or without adding adefovir did not show superiority over 48 weeks PegIFN monotherapy. Lay summary: Extending the duration of pegylated interferon (PegIFN) alfa-2a is not recommended in HBeAg positive patients as treatment extension beyond 48 weeks did not show convincing benefit. Patients who achieved HBsAg <1500 IU/ml or HBV DNA <10 5 copies/ml after 24-week PegIFNa-2a showed satisfac-At present, pegylated interferon (PegIFN) which stimulates the immune response to HBV, and nucleot(s)ide analogs (NAs), which directly suppress viral replication, are the two main first-line therapies recommended by international guidelines [2] [3] [4] . Approximately 30-40% of hepatitis B e antigen (HBeAg) positive CHB patients show a sustained response to PegIFN therapy leading to a relatively high hepatitis B surface antigen (HBsAg) seroclearance rate [5, 6] . However, the remaining 60-70% of patients show an incomplete or partial response. Broadly, two strategies have been proposed for the patients treated with PegIFN: (1) Identification of biomarkers, at baseline or in the early phase of treatment, that can help to identify complete responders and encourage them to complete the standard duration of PegIFN therapy [7] ; and (2) Development of strategies for increasing treatment efficacy for incomplete or partial responders, including extending treatment duration or combining with NAs [8] . These strategies originated from the concept of response-guided therapy (RGT), which has been successfully applied in the management of chronic hepatitis C in the PegIFN era [9] . However, to the best of our knowledge, this approach has not been studied in CHB patients with PegIFN therapy.
Post-hoc analysis of the PegIFNa-2a registration and NEPTUNE studies revealed that 54-57% of HBeAg positive patients who had HBsAg <1500 IU/ml at week 24 achieved HBeAg seroconversion and 7% to 12% of these patients achieved HBsAg loss 6 months after discontinuation of PegIFNa-2a therapy [10, 11] . These patients should be encouraged to complete standard PegIFN treatment.
The more challenging job is to optimize the efficacy of PegIFN in the non-early responders. Various treatment strategies have been tried in the past with different outcomes. The global phase 3 PegIFNa-2a registration study failed to show the benefit of combination with lamivudine at the end of follow-up (EOF) in both HBeAg positive and HBeAg negative patients [12, 13] . Similarly, combination of PegIFN with entecavir (ETV) or sequential treatment with ETV, followed by PegIFN, did not show any added benefit over PegIFN monotherapy [14] . Extending the duration of PegIFNa-2a treatment in HBeAg negative patients from 48 weeks to 96 weeks resulted in improved virological responses (12% vs. 29%) at one-year post-treatment [8] . However, the abovementioned studies testing alternate optimization strategies were conducted on overall treatment naïve patients, and did not take into account on-treatment HBsAg levels.
In this study, we employed quantitative assays for HBsAg and HBV DNA at week 24 as the criteria for evaluating the early response in Chinese HBeAg positive CHB patients. We tried to explore the possibility of applying RGT strategy to the management of patients with PegIFN treatment and to assess whether it is possible to improve the outcomes of non-early responders by extending PegIFN treatment from 48 weeks to 96 weeks, and/or by adding adefovir (ADV).
Materials and methods

Study design and treatment protocol
In this phase IV, prospective, randomized, open-label study (ClinicalTrials.gov number: NCT01086085), all enrolled patients received PegIFNa-2a (Pegasys, Roche, Basel, Switzerlands) 180 lg/week for 24 weeks prior to randomization. Serum HBV DNA and HBsAg level were measured at week 24. Early responders were defined as patients with HBsAg <1500 IU/ml and HBV DNA <10 5 copies/ml (17,182 IU/ml, approximately 20,000 IU/ml) at week 24. Early responders (arm A) continued PegIFNa-2a 180 lg/week for a further 24 weeks (total 48 weeks).
Non-early responders were randomly assigned in a 1:1:1 ratio to arms B, C and D at week 28, by using a block size of 6 according to a computer-generated random schedule using SAS Ò software package version 9.1.3. The fax system was used to assign the treatment to each subject. 
Measurements
Biochemical, virological, and hematological assessments were performed in each center according to locally validated procedures with the exception of HBV DNA, HBV genotype, HBsAg/hepatitis B surface antibody (HBsAb), and HBeAg/HBeAb. ALT levels quantified at each center were transformed to ULN with the center's normal range used as reference. Serum HBV DNA levels were measured centrally using the COBAS TaqMan HBV Test (Roche Molecular Diagnostics, Pleasanton, California, USA; limit of detection 12 IU/ml, 1 IU/ml = 5.82 copies/ml) at commercial laboratory (Clearstone, Beijing). HBV genotypes were determined by polymerase chain reaction sequencing and alignment as reported previously [15] . HBsAg levels were quantified centrally using the Abbott Architect HBsAg assay (Abbott Ireland Diagnostics Division, Sligo, Ireland; dynamic range 0.05-250.0 IU/ ml). Samples with HBsAg >250.0 IU/ml were retested after a dilution of 1:500.
Efficacy assessment
The efficacy analysis included all patients who fulfilled the inclusion criteria and were randomized at week 24 (modified intention to treat [mITT] population). Perprotocol analysis included patients who finished the predefined treatment and follow-up without major protocol deviation. The primary endpoint was the change of quantitative HBsAg from baseline to EOF. The secondary endpoints included the changes from baseline of HBV DNA, rates of ALT normalization, HBeAg loss, HBeAg seroconversion, HBsAg loss and HBsAg seroconversion, HBeAg seroconversion with HBV DNA <2,000 IU/ml at EOT and EOF.
Sample size estimation
The alternative hypothesis of this study was the mean change from baseline of quantitative HBsAg at EOF in either arms C or D was superior to that in arm B.
For arms C vs. B and arms D vs. B in the change of quantitative HBsAg from baseline to EOF, the differences was estimated to be 0.8 log 10 IU/ml and the standard deviation was 1.62 log 10 IU/ml according to the data from HBeAg positive patients with PegIFN treatment in Chinese population [14] . The level of significance was set at 0.05, with power of 80%. Therefore, the estimated sample size was 65 each in arms B, C and D, which was rounded up to 72 to allow for a 10% withdrawal rate (subtotal 216 in arms B, C and D). For arm A, it was estimated that 15% of the subjects could achieve response criteria. Therefore, the sample size for arm A would be 42 (taking into account 10% withdrawal rate). The total sample size required for this study was thus calculated to be 258.
Safety assessments
Safety parameters included clinical adverse events (AEs), laboratory test results, vital signs and physical and ophthalmological examinations during treatment.
The safety analysis was conducted on all patients who had received at least 1 dose of study medication.
Statistical analysis
Statistical analyses were performed using the SAS Ò software package version 9.1.3. Quantitative changes of HBsAg and HBV DNA level, from baseline to EOF, were assessed using an analysis of covariance (ANCOVA) model with treatment arms (B, C and D) and center as fixed factors and baseline levels as covariate.
For the statistical analyses of binary efficacy endpoints, a logistic model incorporating treatment effects in arms (B, C, and D) and the corresponding baseline variables (baseline HBV DNA for HBV DNA negative; baseline HBeAg for HBeAg loss/ HBeAg seroconversion; baseline HBsAg for HBsAg loss/HBsAg seroconversion; both baseline HBeAg and HBV DNA for combined response) were used. For the continuous variables included in the efficacy evaluation, the last observation carried forward procedure was used to impute the missing data pertaining to the treatment period. However, for the missing data pertaining to the follow-up period, no imputation was conducted. For the binary efficacy endpoints, missing values were considered as failures. If the subject received other antiviral therapies, the efficacy data from the start of therapies was set to missing, and no imputation was conducted and was considered as failures for the binary efficacy endpoints. Safety data were summarized using descriptive statistics.
Results
Patient disposition
A summary of subject disposition is presented in 
Baseline characteristics of mITT population
The baseline (Week 0) characteristics of the mITT population were not balanced as they were not randomized at baseline (Table 1) . Patients in arm A had lower baseline HBsAg, HBeAg and HBV DNA but higher ALT than patients in other groups. Patient characteristics in arms B, C and D were comparable, except for slightly higher HBeAg and HBV DNA level in arm B.
With respect to the genotype distribution, more patients in arm A were infected with genotype B HBV.
Week 24 characteristics of non-early responders
As the non-early responders were randomized according to the response at week 24, the characteristics at week 24 among arms B, C and D were balanced in terms of mean HBV DNA, ALT, HBsAg quantitation, HBeAg loss and seroconversion rate ( Table 2 ). The decline of HBsAg from baseline at week 24 was À0.40, À0.36, À0.45 log 10 IU/ml (p = 0.756) for arms B, C and D, respectively.
Efficacy in early responders (Arm A)
In the first 24 weeks, the mean reduction of HBsAg was significantly greater in early responders (arm A, À1.52 log 10 IU/ml), compared with the other three arms (Fig. 3A) . The overall reduction of quantitative HBsAg from baseline to EOF was À1.15 log 10 IU/ml in arm A compared to À0.67 log 10 IU/ml in the non-early responders (p = 0.038) (Fig. 3A) . At EOF, 51.5% and 47.0% of early responders achieved HBeAg loss and seroconversion, that was significantly greater than that observed in non-early responders (p = 0.016 and p = 0.047, respectively). Rates of HBV DNA undetectability, HBeAg seroconversion with HBV DNA <2000 IU/ml were also higher in the early responders as compared to non-early responders (Table 3) . ALT, ×ULN 1.9 ± 2.2 2.1 ± 2.4 1.8 ± 1.6 1.9 ± 2.6 0.709 HBV DNA, log 10 copies/ml 6.2 ± 2.0 6.3 ± 2.0 6.1 ± 1.9 6.2 ± 2.0 0.870
HBsAg, log 10 IU/ml 3.7 ± 0.6 3.8 ± 0.5 3.7 ± 0.7 3.7 ± 0.7 0.777
HBsAg <1500 IU/ml, n (%)
HBeAg, log 10 PEIU/ml 1.3 ± 1.1 1.5 ± 1. At the end of treatment From week 24 to EOT, further decline of HBsAg was observed in the three groups (À0.47 log 10 IU/ml, À0.36 log 10 IU/ml and À0.42 log 10 IU/ml in arms B, C and D, respectively). There was no significant difference in the decrease of HBsAg from baseline to EOT in arm B, when compared with that observed in arms C and D, respectively (B vs. C, p = 0.746; B vs. D, p = 0.461). At EOT, 96 weeks of therapy with PegIFNa-2a in combination with ADV (arm D) resulted in a significantly higher proportion of patients achieving HBeAg loss (35.9% vs. 14.9%, p = 0.022) and seroconversion (31.3% vs. 13.4%, p = 0.041) compared with 48 weeks PegIFNa-2a monotherapy in arm B (Table 3 ). The rates of HBeAg loss and seroconversion were higher in arm C (28.4% and 26.9%), as compared to arm B (14.9% and 13.4%) but without statistical significance. When we combined the arm C and arm D, i.e., all patients with 96 weeks PegIFN therapy, the HBeAg loss and HBeAg seroconversion rate was significantly higher compared to the group of patients receiving the 48 weeks regimen (arm B).
Adding on ADV from week 29 to week 64 resulted in a temporary improvement of viral suppression with a higher HBV DNA reduction from baseline to week 72 (arm C vs. Arm D, À2.49 vs. À3.99 log 10 copies/ml, p <0.001). However, the HBV DNA undetectability rate at EOT was similar between arms C and D.
At the end of follow-up Partial rebound of quantitative HBsAg from EOT to EOF was observed in each arm after the stop of PegIFN (Fig. 3A) . There was no significant difference in the decrease of HBsAg from baseline to EOF in arm B, when compared with that observed in arms C and D, respectively (B vs. C, p = 0.407; B vs. D, p = 0.552). In addition, there were no differences in HBeAg loss and seroconversion for arms B, C and D (Table 3 ). The rate of HBsAg loss was 0%, 1.5% and 3.1% in arms B, C and D respectively. Partial rebound of HBV DNA level was observed in each arm from EOT to EOF. The mean HBV DNA decline from baseline to EOF was À2.34, À2.68 and À2.83 log 10 copies/ml in arms B, C and D, respectively (Fig. 3B) . There was no significant difference between arm C vs. arm B or arm D vs. arm B in terms of HBV DNA undetectability, HBeAg seroconversion with HBV DNA <2000 IU/ml (Table 3) . Per-protocol analysis also showed that the response at EOF among arms B, C and D were not different (Supplementary Table 1 ).
Prediction of response Fig. 4 shows the chance of response according to the levels of HBsAg (<1500 vs. P1500 IU/ml) and/or HBV DNA (<5 vs.
P5 log copies/ml) at week 24. 38.4% of patients with HBsAg <1500 IU/ml at week 24 achieved HBeAg seroconversion with HBV DNA <2000 IU/ml at EOF, similarly, 37.0% of patients with HBV DNA <5 log copies/ml at week 24 also achieved this response at EOF. When we combined HBsAg and HBV DNA levels at week 24, only patients with HBsAg >1500 IU/ml plus HBV DNA >5 log copies/ml showed relatively poor response (HBeAg seroconversion with HBV DNA <2000 IU/ml rate 13.6% at EOF). Patients infected with genotype B had a numerically higher rate of HBeAg seroconversion with HBV DNA <2000 IU/ml compared with those infected with genotype C; however, this difference was not statistically significant (Supplementary Fig. 1) . Notably, 17.7% (8/45) of patients with HBsAg >20,000 IU/ml at week 12 and 14.3% (5/35) of patients with HBsAg >20,000 IU/ml at week 24 still achieved HBeAg seroconversion with HBV DNA <2000 IU/ml at EOF. When we only included patients with 48 weeks PegIFN treatment, 17.6% (3/17) of patients with HBsAg >20,000 IU/ml at week 12 and 7.7% (1/13) of patients with HBsAg >20,000 IU/ml at week 24 achieved HBeAg seroconversion with HBV DNA <2000 IU/ml at EOF.
Safety
The safety analysis included 265 patients who received at least 1 dose of study drug. Treatment was generally well tolerated. A total of 262 patients (98.9%) experienced AEs with more AEs being mild to moderate in severity. Four patients discontinued treatment due to AEs (two each in arms C and D) and four patients discontinued follow-up due to AEs (one each in arms A, B, C and D). No deaths were reported during the study period (Table 4 ). The most common AEs were pyrexia and decreased neutrophil count. Arm D (with ADV) was associated with a higher incidence of leucopenia, neutropenia, thrombocytopenia, and increased ALT levels than arms B and C. All of the serious AEs resolved by the end of study.
Discussion
RGT is a promising approach which has been successfully applied to the treatment of chronic hepatitis C. To the best of our The most common AEs, n (%) knowledge, this is the first randomized, controlled study to apply the concept of RGT in CHB. For patients who achieved HBsAg <1500 IU/ml or HBV DNA <10 5 copies/ml at week 24, the response was optimal with 38.4% and 37.0% respectively achieving HBeAg seroconversion with HBV DNA <2000 IU/ml at EOF. Extending PegIFN treatment duration or adding on ADV, did not show superiority over 48 weeks PegIFN monotherapy. On-treatment HBsAg levels have been shown in retrospective analyses to be strongly related with post-treatment response to PegIFN. However, this rationale has not been confirmed by any prospective study. Our study is the first study which prospectively demonstrated that patients with HBsAg <1500 IU/ml at week 24 gained favorable sustained response to PegIFN treatment. Taken together, for 86 patients with HBsAg <1500 IU/ml at week 24, the sustained response rate (HBeAg seroconversion with HBV DNA <2000 IU/ml at EOF) was 38.4%. The rationale for combining HBsAg quantitation with HBV DNA level for defining early response at week 24 originated from the study by Fried et al. [16] which showed that 53% of patients with HBV DNA <5 log copies/ml at week 24 achieved HBeAg seroconversion at 24 weeks post-treatment. Our study results also confirmed that week 24 HBV DNA as well as week 24 HBsAg level can predict the outcomes at EOF. It is reasonable to infer that combining these two strong efficacy predictors may be helpful for patient management. In our study, for patients achieving HBV DNA <10 5 copies/ml plus HBsAg <1500 IU/ml at week 24, 38.8%
showed sustained response at EOF with HBeAg seroconversion and HBV DNA <2000 IU/ml. However, the response rate is comparable to patients with HBV DNA <10 5 copies/ml or HBsAg <1500 IU/ml at week 24 (Fig. 4) . Only for patients with 24-week HBsAg >1500 IU/ml and HBV DNA >5 log 10 copies/ml was the response rate relatively lower. Therefore, patients with HBsAg <1500 IU/ml or HBV DNA <5 log 10 copies/ml should be encouraged to continue PegIFN treatment since they have a high chance of achieving sustained response off-treatment. Interestingly, in early responders in our study, 24 weeks of treatment resulted in HBsAg reduction of À1.52 Log 10 IU/ml, 25.8% HBeAg loss and HBeAg seroconversion rate. Another 24 weeks PegIFN treatment from week 24 to week 48 did not provide significant additional benefit for these patients, with no further decline of HBsAg, and minimal increase of HBeAg loss and seroconversion rate. It merits further study to compare short duration of 24 weeks vs. 48 weeks for the early responders. We will present the in-depth analysis result in a future publication to propose which patients could benefit from a shortened therapy period of 24 weeks based on rapid response as early as week 12.
Trying to increase response rate for non-early responders is always difficult. In this study, extending PegIFN from 48 weeks to 96 weeks with or without combining adefovir, did not lead to more benefit for non-early responders in terms of primary or secondary endpoints at EOF. Several studies have demonstrated the potential benefit of extending interferon treatment duration, mainly focused on HBeAg negative patients [8, 17] . Lampertico et al. reported significantly higher virological response rates (HBV DNA <2000 IU/ml) at EOF after extending PegIFNa-2 therapy from 48 weeks to 96 weeks, in a cohort of HBeAg negative CHB patients [8] . Of note, there was no significant difference in virological response at EOT. The benefit of extending PegIFN duration in HBeAg negative patients is aimed at decreasing relapse rate after PegIFN withdrawal. However, extending treatment duration in HBeAg positive patients is a different story from HBeAg negative patients. In our study in HBeAg positive patients, extending the treatment duration from 48 weeks to 96 weeks in non-early responders (arm C + D vs. arm B) resulted in higher HBeAg loss and seroconversion response at EOT, but not at EOF. This result suggested that extending PegIFN therapy in HBeAg positive patients just speeded up the HBeAg seroconversion, but did not increase the overall off-treatment response.
Currently, combination therapy of NAs with PegIFN is not recommended by international guidelines because of unproven superior efficacy [18] . In the present study, for treatmentexperienced patients who do not achieve early response to PegIFN, addition of ADV only resulted in transient reduction of HBV DNA level, which rebounded after stopping ADV. The addition of ADV did not improve other efficacy endpoints either, such as HBsAg reduction, HBeAg seroconversion and HBeAg loss. For treatment naïve patients, most studies testing the efficacy of combination therapy of PegIFNa-2a plus NAs in HBeAg positive CHB have shown disappointing results. The classical PegIFNa2a and alfa-2b global registration study failed to demonstrate the benefit of combination with lamivudine at EOF [13, 19] . Furthermore, a recent Chinese multicenter study demonstrated no additional benefit in terms of serological and virological response with PegIFN plus ETV regimen, or PegIFN therapy with ETV pretreatment, over that attained with PegIFN monotherapy [14] . On the contrary, the result of a recent study showed that PegIFN combined with tenofovir could achieve greater decline of HBsAg level, as well as higher rate of HBsAg loss, but the benefit is not significant when we only focused on patients with genotype B and C [20] . Therefore, based on the above results, we proposed that the benefit of adding on NAs during PegIFN treatment for non-responders is limited, which is not encouraged, especially in patients infected with genotype B or C.
Stopping rules have been proposed recently to guide PegIFN treatment in HBeAg positive patients based on HBsAg level at week 12 or 24 according to different genotypes [7] . Treatment discontinuation is indicated in all patients with HBsAg >20,000 IU/ml at week 24, irrespective of HBV genotype. However, this rule did not work very well in our region. In our study, 14.3% of patients with HBsAg >20,000 IU/ml at week 24 still achieved HBeAg seroconversion with HBV DNA <2000 IU/ml at EOF. This has also been illustrated previously by the PegIFNa 2a registration study which showed that 16% patients achieved HBeAg seroconversion even if HBsAg was >20,000 IU/ml at week 24 [10] . As the genotype distribution differs among regions, we need more careful evaluation of the stopping rule in Chinese HBeAg positive patients with validation data from different studies.
Extending PegIFNa-2a duration and combination of PegIFNa2a with ADV were both well tolerated. The safety assessment did not reveal any major concerns and the reported AEs were consistent with the know safety profile of PegIFN and ADV [13, 21] . A few subjects (4.9%) experienced serious AEs, however, no deaths were reported. Totally, 33 patients dropped out before EOF, but only 8 of them were due to AEs. Non-compliance was an important issue for the PegIFN extension groups.
As this was the first attempt to try RGT strategy in CHB patients, some limitations in our study were inevitable. Using HBsAg reduction as primary endpoint was perhaps a suboptimal primary endpoint. However, if we kept the same study design and used HBeAg loss or seroconversion as the primary endpoint, the estimated sample size requirement would have been over 800, which was not feasible owing to the budgetary constraints. In addition, HBsAg quantitation has been extensively studied in patients treated with PegIFN [7, 10, 11, 22, 23] . Several pivotal studies have shown that greater reduction of HBsAg levels indicated better treatment outcomes [22] [23] [24] . HBsAg reduction is also the prerequisite to achieve HBsAg clearance. Based on this rationale, HBsAg reduction is still a meaningful endpoint, especially in future study designs targeting HBsAg clearance. Another shortcoming was the high dropout rate observed in the study group treated with 96 weeks PegIFNa-2a. This probably underestimated the benefit of extending treatment duration since all cases with incomplete data were considered as treatment failure. However, a per-protocol analysis was also performed, which showed consistent results to that the ITT analysis. A reduction in the dosage of PegIFNa-2a to 135 microgram per week in the period from 48 weeks to 96 weeks could probably improve treatment compliance [8] . Finally, adefovir is not the preferred first-line anti-HBV drug according to international guidelines. However, as this study is the first proof of concept study trying to optimize the treatment outcome by combining PegIFN with NAs in patients who did not achieve early response to PegIFN, the finding from the present study are important for the design of future studies combining PegIFN with other NAs.
To conclude, this study proved that RGT was practical for CHB patients. Extending the duration of PegIFN in non-early responders is not recommended in Chinese HBeAg positive patients as treatment extension beyond 48 weeks did not show convincing benefit in terms of serologic or virologic response. Patients who achieved an early response defined as HBsAg <1500 IU/ml or HBV DNA <10 5 copies/ml at week 24 showed satisfactory outcome after the withdrawal of finite PegIFN treatment.
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